Retatrutide for Heart Failure: Off-Label Risks, Tradeoffs, and What the Evidence Actually Shows

What Is Retatrutide and Why Is It Being Discussed for Heart Failure?

Retatrutide (LY3437943) is an investigational peptide that activates three incretin and metabolic receptors at once: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon [1]. Eli Lilly is developing it primarily for obesity and type 2 diabetes, with phase 3 trials (TRIUMPH program) ongoing but not yet yielding approval-ready results.

The heart failure conversation exists because of two converging factors. First, obesity is a root driver of heart failure with preserved ejection fraction (HFpEF), and retatrutide produced the largest weight reductions ever recorded in a phase 2 drug trial [1]. Second, GLP-1 receptor agonists (a drug class that overlaps with one of retatrutide's three targets) have demonstrated direct cardiovascular benefits in completed outcomes trials [2,3]. Clinicians treating obese patients with concurrent HFpEF have begun asking whether retatrutide's pronounced weight loss could translate into cardiac benefit. That question has no answer from controlled data. The evidence base is entirely indirect.

The Phase 2 Obesity Data: What We Know About Retatrutide's Effects

Retatrutide's primary clinical dataset comes from a 48-week, dose-ranging phase 2 trial published in the New England Journal of Medicine by Jastreboff et al. [1]. The trial enrolled 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27 with at least one weight-related comorbidity) and randomized them across multiple dose arms versus placebo.

Results were striking. The 12 mg dose group achieved 24.2% mean body weight loss at 48 weeks, compared with 2.1% in the placebo arm [1]. The 8 mg group lost 22.8%. These reductions exceeded those seen with tirzepatide (up to 22.5% in SURMOUNT-1 at 72 weeks) and semaglutide 2.4 mg (14.9% in STEP-1 at 68 weeks) [4,5].

Cardiovascular safety signals in that trial were limited by sample size. Heart rate increased by a mean of 2 to 4 beats per minute in higher-dose groups [1]. Gastrointestinal adverse events (nausea, diarrhea, vomiting) were the most common side effects, occurring in 35% to 60% of participants depending on dose and titration schedule. No major adverse cardiovascular events (MACE) occurred, but the trial was neither designed nor powered to detect them. The enrolled population excluded patients with NYHA class III or IV heart failure.

Why GLP-1 Receptor Agonist Data Cannot Be Directly Applied to Retatrutide

The strongest cardiovascular evidence for the incretin drug class comes from semaglutide. Two trials are directly relevant.

STEP-HFpEF (N=529) randomized patients with HFpEF and BMI ≥30 to semaglutide 2.4 mg weekly or placebo for 52 weeks. Semaglutide produced a 7.8-point improvement in the Kansas City Cardiomyopathy Questionnaire clinical summary score (vs. 1.8 points for placebo), a 13.3% mean weight reduction, and a significant decrease in C-reactive protein [3]. This trial established that a GLP-1 receptor agonist could improve symptoms and functional status in obese HFpEF patients.

SELECT (N=17,604) tested semaglutide 2.4 mg in patients with established atherosclerotic cardiovascular disease and obesity but without diabetes. Semaglutide reduced the composite MACE endpoint by 20% (hazard ratio 0.80, 95% CI 0.72 to 0.90) [2]. The trial confirmed cardiovascular risk reduction from GLP-1 receptor agonism in an obese population with existing heart disease.

These results, while encouraging, describe a single-receptor agonist. Retatrutide adds GIP and glucagon receptor activation on top of GLP-1 agonism. Each additional receptor introduces distinct pharmacology that could either amplify or undermine the cardiovascular profile seen with semaglutide alone.

The Glucagon Receptor Problem: A Specific Cardiac Concern

Glucagon receptor agonism is the feature that most sharply distinguishes retatrutide from tirzepatide (dual GIP/GLP-1) and semaglutide (GLP-1 only). It is also the feature that raises the most direct concern for heart failure patients.

Glucagon increases heart rate, myocardial contractility, and cardiac output [6]. In acute settings, intravenous glucagon has historically been used as a temporizing measure for beta-blocker overdose precisely because it stimulates the heart independently of beta-adrenergic pathways [7]. These are beneficial properties in a poisoning scenario. They are potentially harmful in a failing heart that already operates under increased wall stress and oxygen demand.

Chronic, low-level glucagon receptor activation from a weekly subcutaneous injection differs pharmacologically from an acute IV bolus. The degree of cardiac stimulation at therapeutic doses of retatrutide remains unquantified in patients with compromised ventricular function. Animal models of glucagon receptor agonism show increased hepatic glucose output and lipolysis (desirable for weight loss) but also elevated resting energy expenditure, which in a patient with reduced cardiac reserve could worsen exercise intolerance or precipitate decompensation [6].

No published study has measured retatrutide's hemodynamic effects in patients with heart failure of any subtype. The 2 to 4 bpm heart rate increase observed in the obesity trial [1] is modest, but heart failure patients are a different population. Small heart rate elevations have prognostic significance in HFrEF, where each 5 bpm increase in resting heart rate has been associated with a 16% increase in cardiovascular mortality [8].

GIP Receptor Agonism: Uncertain Cardiac Effects

GIP receptor activation in the cardiovascular system is less well characterized than GLP-1 or glucagon signaling. Preclinical data suggest GIP may have both cardioprotective and neutral properties, but human cardiovascular outcomes data for isolated GIP agonism do not exist [9].

Tirzepatide, a dual GIP/GLP-1 agonist, provides the closest clinical analogy. The SURPASS-CVOT trial (later named SUMMIT for the HFpEF population) tested tirzepatide in patients with HFpEF and obesity. Tirzepatide 15 mg reduced the composite of cardiovascular death or worsening heart failure events by 38% (HR 0.62, 95% CI 0.41 to 0.95) and improved exercise capacity at 52 weeks [10]. This suggests that dual agonism (GIP plus GLP-1) is at minimum not harmful in HFpEF and may be actively beneficial.

Whether adding a third receptor (glucagon) to this combination preserves, enhances, or negates those benefits is the core unanswered question. The TRIUMPH phase 3 program for retatrutide does not include a dedicated heart failure arm.

Grading the Evidence: How Weak Is the Case for Retatrutide in HF?

Applying the GRADE framework to the question "Should retatrutide be used in patients with heart failure?" yields a rating of very low certainty. Here is the reasoning:

The evidence is entirely indirect. No randomized trial, observational cohort, or case series has evaluated retatrutide in heart failure patients. The supporting data come from different drugs (semaglutide, tirzepatide), different populations (obese patients without HF), and different receptor profiles (single or dual agonism, not triple). The phase 2 obesity trial excluded NYHA III/IV patients and was not powered for cardiovascular endpoints [1].

Mechanistic plausibility exists. GLP-1 receptor agonism has direct myocardial and endothelial effects that are cardioprotective in preclinical models [11]. Weight reduction of 10% or more improves left ventricular filling pressures, reduces epicardial adipose tissue, and lowers circulating inflammatory markers in obese HFpEF patients [3,12]. Retatrutide achieves weight reductions exceeding 20%, which could theoretically produce even larger hemodynamic benefits.

But mechanistic plausibility is not efficacy data. The Endocrine Society and American College of Cardiology have not issued guidance on retatrutide use in any population, given its investigational status [13]. The FDA has approved no indication for this drug. Prescribing it for heart failure would constitute off-label use of an unapproved compound, a regulatory and medicolegal category that carries heightened liability.

Risks Specific to Heart Failure Patients

Several risks warrant attention for any clinician considering retatrutide in a heart failure population.

Volume depletion. Retatrutide causes significant nausea and reduced oral intake, particularly during dose titration [1]. Heart failure patients on loop diuretics are already at risk for hypovolemia, prerenal azotemia, and electrolyte disturbances. Adding a drug that suppresses appetite and fluid intake could precipitate acute kidney injury or dangerous hypokalemia.

Lean mass loss. Rapid weight loss from incretin-based therapies includes both fat mass and lean body mass. In the STEP-1 trial, approximately 40% of total weight lost was lean mass [4]. Heart failure patients, particularly those with HFrEF, already experience cardiac cachexia and sarcopenia. Accelerated lean mass depletion could worsen functional capacity even as fat mass decreases.

Drug interactions. Retatrutide slows gastric emptying, which may alter the absorption kinetics of narrow-therapeutic-index drugs commonly used in heart failure: digoxin, warfarin, and certain formulations of loop diuretics [1]. No formal drug-interaction studies in HF polypharmacy regimens have been conducted.

Heart rate. As discussed above, the observed 2 to 4 bpm increase from glucagon receptor agonism may be clinically relevant in patients with HFrEF on optimized beta-blocker therapy, where the therapeutic goal is a resting heart rate of 60 to 70 bpm [8].

Unknown long-term cardiac effects. The longest retatrutide exposure in published data is 48 weeks in 338 patients without heart failure [1]. The cardiovascular safety profile in longer-term use, in sicker populations, and at the higher doses that produce the most weight loss remains completely undefined.

What Would Need to Be True Before Retatrutide Could Be Recommended for HF

A responsible pathway from current evidence to a clinical recommendation would require several sequential steps.

First, the TRIUMPH phase 3 program would need to demonstrate an acceptable cardiovascular safety profile in its primary obesity and diabetes populations. This means completing enrollment, reaching prespecified endpoints, and undergoing FDA review.

Second, a dedicated cardiovascular outcomes trial (CVOT) in patients with established heart failure (likely HFpEF, given the obesity overlap) would need to be designed, enrolled, and completed. This trial would need to be powered for hard endpoints: cardiovascular death, heart failure hospitalization, or urgent heart failure visits. Based on precedent from SELECT (4-year median follow-up) and STEP-HFpEF (52 weeks), such a trial would require 1,000 to 5,000 patients followed for 1 to 4 years [2,3].

Third, hemodynamic substudies measuring the effect of triple agonism on filling pressures, cardiac output, and pulmonary artery pressures would need to confirm that the glucagon component does not worsen cardiac mechanics in the setting of elevated wall stress.

Until these data exist, prescribing retatrutide for heart failure is not supported by evidence-based medicine criteria. The Endocrine Society's 2024 clinical practice guideline on pharmacological treatment of obesity recommends FDA-approved GLP-1 receptor agonists for patients with obesity and cardiovascular disease but does not address investigational agents [13].

How Retatrutide Compares to Approved Options for Obese HF Patients

Clinicians treating obese patients with heart failure have two incretin-based agents with actual cardiovascular outcomes data.

Semaglutide 2.4 mg (Wegovy) is FDA-approved for chronic weight management and carries a cardiovascular risk reduction indication based on SELECT [2]. STEP-HFpEF supports its use in obese HFpEF specifically [3]. The evidence base includes over 18,000 patients across these two trials.

Tirzepatide (Zepbound) is FDA-approved for chronic weight management. SUMMIT demonstrated a 38% reduction in cardiovascular death or worsening heart failure in HFpEF patients with obesity [10]. Its dual GIP/GLP-1 mechanism provides a partial pharmacologic bridge toward understanding what triple agonism might do, but it lacks the glucagon component.

Both drugs have known safety profiles in heart failure patients, published dosing protocols, established drug-interaction data, and regulatory approval. Choosing retatrutide over either of these options means accepting unknown risks for speculative additional benefit. The marginal weight loss advantage of retatrutide (roughly 2 to 5 percentage points more than tirzepatide at 48 weeks) has not been shown to translate into incremental cardiac benefit [1].

Clinical Bottom Line

Retatrutide has no FDA-approved indication, no completed phase 3 trial, and zero data in heart failure patients. Its triple-receptor mechanism includes glucagon agonism, which could increase myocardial oxygen demand in a population that tolerates such increases poorly. Two FDA-approved alternatives (semaglutide and tirzepatide) have direct HFpEF trial data supporting their use.

The American Heart Association's 2023 scientific statement on obesity and heart failure recommends weight management as a therapeutic target in HFpEF but specifies agents with proven cardiovascular safety [12]. Retatrutide does not meet that threshold. Clinicians should direct obese heart failure patients toward semaglutide 2.4 mg (if ASCVD risk reduction is a priority) or tirzepatide (if maximum weight loss with demonstrated HFpEF benefit is preferred), with dosing adjustments to account for diuretic interactions and volume status, and reassess the retatrutide evidence base only after the TRIUMPH program reports cardiovascular safety data [10].